Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > BIIB Biogen > Detailed Quotes

BIIB Biogen

Watchlist
210.630
+6.690+3.28%
Close 07/01 16:00 ET
210.500
-0.13-0.06%
Post Mkt Price 07/01 19:58 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
210.750
Open
205.370
Turnover
167.20M
Low
203.920
Pre Close
203.940
Volume
800.86K
Market Cap
30.85B
P/E(TTM)
21.56
52wk High
372.115
Shares
146.45M
P/E(Static)
20.25
52wk Low
187.160
Float Cap
30.76B
Bid/Ask %
33.33%
Historical High
480.180
Shs Float
146.03M
Volume Ratio
0.50
Historical Low
2.625
Dividend TTM
--
Div Yield TTM
6000
P/B
2.74
Dividend LFY
--
Div Yield LFY
2848.60%
Turnover Ratio
0.55%
Amplitude
3.35%
Avg Price
208.778
Lot Size
1
Float Cap
30.76B
Bid/Ask %
33.33%
Historical High
480.180
Shs Float
146.03M
Volume Ratio
0.50
Historical Low
2.625
Dividend TTM
--
P/B
2.74
Dividend LFY
--
Turnover Ratio
0.55%
Amplitude
3.35%
Avg Price
208.778
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
CEO: Vounatsos, Michel
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top